144 related articles for article (PubMed ID: 38697177)
1. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.
Rubio JM; Kane JM; Tanskanen A; Tiihonen J; Taipale H
Lancet Psychiatry; 2024 Jun; 11(6):443-450. PubMed ID: 38697177
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
[TBL] [Abstract][Full Text] [Related]
3. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
BMC Psychiatry; 2016 Dec; 16(1):441. PubMed ID: 27955666
[TBL] [Abstract][Full Text] [Related]
4. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis.
Hägg S; Rosenius S; Spigset O
Int Clin Psychopharmacol; 2003 May; 18(3):173-4. PubMed ID: 12702898
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland.
Taipale H; Solmi M; Lähteenvuo M; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2021 Oct; 8(10):883-891. PubMed ID: 34474013
[TBL] [Abstract][Full Text] [Related]
6. Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted.
Lahdelma L; Appelberg B
J Clin Psychiatry; 2012 Jun; 73(6):837-42. PubMed ID: 22480452
[TBL] [Abstract][Full Text] [Related]
7. Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis.
Hazewinkel AW; Bogers JP; Giltay EJ
Gen Hosp Psychiatry; 2013; 35(5):576.e11-2. PubMed ID: 23395419
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
[TBL] [Abstract][Full Text] [Related]
9. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
10. Clozapine dose for schizophrenia.
Subramanian S; Völlm BA; Huband N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009555. PubMed ID: 28613395
[TBL] [Abstract][Full Text] [Related]
11. Hematological adverse events in clozapine-treated children and adolescents.
Gerbino-Rosen G; Roofeh D; Tompkins DA; Feryo D; Nusser L; Kranzler H; Napolitano B; Frederickson A; Henderson I; Rhinewine J; Kumra S
J Am Acad Child Adolesc Psychiatry; 2005 Oct; 44(10):1024-31. PubMed ID: 16175107
[TBL] [Abstract][Full Text] [Related]
12. [Ten years of clinical experience with clozapine about 170 patients].
Levoyer D; Martinet JP; Badiche A; Millet B
Encephale; 2004; 30(3):285-95. PubMed ID: 15235527
[TBL] [Abstract][Full Text] [Related]
13. Psychopharmacology. Clozapine and agranulocytosis.
Feldman J
Psychiatr Serv; 1996 Nov; 47(11):1177-8. PubMed ID: 8916231
[No Abstract] [Full Text] [Related]
14. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis.
Tiwari AK; Need AC; Lohoff FW; Zai CC; Chowdhury NI; Müller DJ; Putkonen A; Repo-Tiihonen E; Hallikainen T; Yağcıoğlu AE; Tiihonen J; Kennedy JL; Meltzer HY
Mol Psychiatry; 2014 Apr; 19(4):403-5. PubMed ID: 23752246
[No Abstract] [Full Text] [Related]
15. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients.
Coşar B; Taner ME; Eser HY; Altınöz AE; Tarhan R
J Clin Psychopharmacol; 2011 Apr; 31(2):169-73. PubMed ID: 21346615
[TBL] [Abstract][Full Text] [Related]
16. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in jewish Israeli schizophrenic patients.
Meged S; Stein D; Sitrota P; Melamed Y; Elizur A; Shmuelian I; Gazit E
Int Clin Psychopharmacol; 1999 Sep; 14(5):305-12. PubMed ID: 10529073
[TBL] [Abstract][Full Text] [Related]
18. A follow-up study of a population of schizophrenic patients treated with clozapine.
Bourin M; Guitton B; Dailly E; Hery P; Jolliet P
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Nov; 25(8):1481-95. PubMed ID: 11642649
[TBL] [Abstract][Full Text] [Related]
19. Clozapine treatment in Australia: a review of haematological monitoring.
Copolov DL; Bell WR; Benson WJ; Keks NA; Strazzeri DC; Johnson GF
Med J Aust; 1998 May; 168(10):495-7. PubMed ID: 9631674
[TBL] [Abstract][Full Text] [Related]
20. Clozapine: the commitment to patient safety.
Alphs LD; Anand R
J Clin Psychiatry; 1999; 60 Suppl 12():39-42. PubMed ID: 10372610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
